Gilead Sciences (NASDAQ:GILD) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.

GILD has been the topic of a number of other reports. Berenberg Bank set a $96.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, October 19th. Royal Bank of Canada started coverage on shares of Gilead Sciences in a report on Thursday, September 14th. They set an “outperform” rating and a $94.00 target price on the stock. J P Morgan Chase & Co set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, October 25th. Robert W. Baird restated an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a report on Tuesday, August 29th. Finally, Wells Fargo & Company restated a “market perform” rating and set a $81.00 target price (up from $73.00) on shares of Gilead Sciences in a report on Thursday, August 31st. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $85.11.

Shares of Gilead Sciences (NASDAQ:GILD) opened at $75.57 on Thursday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences has a fifty-two week low of $63.76 and a fifty-two week high of $86.27. The stock has a market cap of $98,714.75, a P/E ratio of 7.89, a PEG ratio of -1.27 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The company had revenue of $6.51 billion for the quarter, compared to the consensus estimate of $6.40 billion. During the same period last year, the company earned $2.75 earnings per share. The firm’s revenue was down 13.2% compared to the same quarter last year. sell-side analysts predict that Gilead Sciences will post 8.53 EPS for the current fiscal year.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $82.56, for a total value of $6,054,372.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total transaction of $16,033,600.00. The disclosure for this sale can be found here. In the last three months, insiders sold 494,999 shares of company stock valued at $37,404,139. 1.30% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its position in Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock worth $7,425,281,000 after purchasing an additional 1,937,031 shares during the period. Vanguard Group Inc. lifted its position in Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock worth $6,571,355,000 after purchasing an additional 2,148,697 shares during the period. Bank of New York Mellon Corp lifted its position in Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after purchasing an additional 310,607 shares during the period. FMR LLC lifted its position in Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock worth $1,630,581,000 after purchasing an additional 258,005 shares during the period. Finally, Northern Trust Corp lifted its position in Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock worth $1,162,949,000 after purchasing an additional 116,780 shares during the period. 76.23% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “BidaskClub Upgrades Gilead Sciences (GILD) to “Hold”” was first posted by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/12/17/bidaskclub-upgrades-gilead-sciences-gild-to-hold.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.